Atrial fibrillation (AF) and heart failure (HF) are epidemic cardiac diseases and are often detected in the same patient. Recent evidence suggests that this is not a mere coincidence but that the strategy of AF treatment may impact HF development. This review comprehensively summarizes current trial data on rhythm and rate control strategies in atrial fibrillation with a special focus on catheter ablation of AF in HF patients. For a long time, rate and rhythm control strategies for AF have been regarded as equal regarding long term mortality. Decision making has been based on the symptoms of patients. Current trials, however, show that the treatment strategy of AF and its effectiveness may significantly impact survival of HF patients. The benefits of rhythm control in HF patients may have been masked by side effects of antiarrhythmic drugs. If rhythm control, however, is achieved by catheter ablation, a reduction of HF related mortality can be observed. As catheter ablation of AF may reduce mortality in HF patients, AF ablation should be preferred over medical treatment in HF patients. In general, HF patients may profit most from rigorous AF treatment.
| PREVALENCE AND RISK FACTORS OF ATRIAL FIBRILLATION
Atrial Fibrillation (AF) is by far the most common sustained arrhythmia and one of the most challenging ones to treat. By the year 2030, there will be an estimated 14-17 million patients with AF in the European Union. 1 It is a worldwide leading cause of hospitalizations and cardiovascular death accounting for 35% of all arrhythmia-related hospital admissions. 2 Without appropriate therapy, patients are confronted with a 1.5-1.9-fold increased risk for death as well as a 5-fold increased risk for stroke and thromboembolic events. 3, 4 As AF is a heterogeneous and multifactorial rhythm disorder, different clinical presentations from self-limiting paroxysmal AF to permanent AF are observed. Up to date, the mechanisms of sustained AF and the nature of arrhythmogenic substrates are still a matter of debate and inter-individual differences between patients most likely account for inconsistencies. 5 Importantly, recent longitudinal data from the Framingham Heart Study 6 highlighted the fact that the risk factor burden and the existence of multiple morbidities have a crucial role in the lifetime risk of atrial fibrillation. Participants with at least one elevated risk factor were confronted with a lifetime AF risk as high as 37.8%. 6 Of note, diabetes mellitus seems to be a major factor for the development of AF. Patients with diabetes mellitus were shown to have a lifetime risk of AF of approximately 40%. 7 This could be explained by the strong relationship between autonomic dysfunction in diabetic patients and AF. 8 In line with this, diabetes has been shown to be associated with an increased risk of stroke, even in younger patients. 9 Other less well-studied risk factors, such as chronic obstructive pulmonary disease, are also linked to AF, 10 which is probably driven by systemic inflammation. 11 
| ATRIAL FIBRILLATION AND HEART FAILURE
Currently, an important and increasingly concerning topic is the treatment of AF in patients with heart failure (HF), which despite recent advances in HF-therapy still continues to be a high-mortality disease. [12] [13] [14] Beatriz Tose Costa Paiva and Thomas H. Fischer contributed equally to this study (shared first author).
The correlation between both entities was first described in 1937, when Paul Dudley White stated: "Since auricular fibrillation so often complicates very serious heart disease, its occurrence may precipitate heart failure or even death, unless successful therapy is quickly instituted." How wise this statement was, however, could only be proven in the last couple of years. Indeed, both diseases significantly interplay. Whenever AF and HF coincide, high morbidity and mortality rates are encountered. The incidence of AF and HF is estimated to be around 1%-2% in adults 15 and the prevalence of both diseases increases with age. HF is encountered in more than 10% of over 70-year-olds 14 and AF in nearly 10% in the octogenarian population. 16 Interestingly, up to 50% of patients with HF suffer from AF. 2, 16 Furthermore, the severity of HF facilitates the occurrence of AF. HF patients classified as New York Heart Association (NYHA) I show an AF prevalence of <5%, while patients with NYHA IV symptoms have an AF prevalence of up to 50%.
2,17
On the other hand, AF can lead to tachycardia induced cardiomyopa- As TIC is often promptly reversible within a short-time period after successful treatment of the underlying arrhythmia, recognizing this condition and offering an early appropriate therapy of the underlying pathology is primordial to improve outcomes. In this context, late gadolinium enhanced cardiac magnetic resonance (CMR) imaging identifies irreversible structural change and may predict incomplete recovery of LV function. In the absence of scar, ventricular function normalizes with a high probability following the restoration of sinus rhythm. 19 Furthermore, LV scar extension has been shown as independent predictor for atrial fibrillation and major adverse cardiac and cerebrovascular events. 20, 21 Apart from TIC, restoration and maintenance of sinus rhythm (SR) in AF patients with HF in general is an approach to decrease symptoms. Upon the reestablishment of SR, HF patients potentially benefit from atrial contraction improving diastolic filling and the restoration of atrio-ventricular sequential activation. Conclusively, a relief of HF related symptoms was observed upon cardiac rhythm control. 18, 22 However, until recently, randomized trials failed to prove that the hemodynamic benefits of rhythm control strategies translate into decreased mortality.
| PHARMACOLOGICAL RHYTHM VS RATE CONTROL IN HEART FAILURE PATIENTS
Rhythm and rate control strategies are the cornerstone in the treatment of AF. Both strategies aim at improving symptoms.
Several important studies have assessed the outcomes of pharmacological rhythm control in AF patients additionally suffering from heart failure with reduced ejection fraction (HFrEF). In the Danish
Investigators of Arrhythmia and Mortality on Dofetilide in Congestive
Heart Failure (DIAMOND-CHF) trial, 23 published in 2001, 1518
patients were randomized to receive either dofetilide (n = 762) or placebo (n = 758). Study data revealed that 65% of patients randomized to dofetilide therapy were in SR compared to 30% of patients in the placebo group. The dofetilide arm was associated with less frequent hospitalizations due to AF (P < 0.001; hazard ratio 0.75; 95% confidence interval, 0.63-0.89). However, no significant difference in overall mortality was observed between both groups (311 patients = 41%
in dofetilide arm vs 317 = 42% in the placebo group). [23] [24] [25] Moreover, another large multicenter randomized trial published in 2008 (Atrial Fibrillation and Congestive Heart Failure trial, AF-CHF) 26 compared mortality between rhythm and rate control treatment strategies in 1376 AF patients with left ventricular ejection fraction (LVEF) <35% and symptoms of congestive HF. Primary endpoint was the time to cardiovascular death. Of the study group, 682 patients were randomized to rhythm control group vs 694 to rate control group.
Antiarrhythmic drugs (AAD) like amiodarone, sotalol and dofetilide as well as electrical cardioversion were used as rhythm control strategy.
In the rate control-arm, beta-blockers and cardiac glycosides were administered. In line with previous studies, cardiovascular death rate was similar in both groups (27% in rhythm control vs 25% under rate control, P = 0.59) after a mean follow-up period of 37 months. Again, overall mortality did not differ either (32% vs 33%, P = 0.68). Patients on rhythm control, however, had to be hospitalized more frequently in the first year (46% vs 39%, P = 0.001), which can be attributed to the need of repeated electrical cardioversion (59% vs 9%, P < 0.001) and antiarrhythmic therapy adjustment. In this study, the percentage of SR in the rhythm control group was relatively high (70%-80%) but with a considerable number of patients on amiodarone regimen. 26 In total, 82% of patients in the rhythm control arm received amiodarone vs 7% in the rate control group.
These results raised doubts about a valuable benefit of rhythm over rate control strategies in patients with co-existing AF and HFrEF.
The fact that rhythm control strategies did not translate into an improved outcome despite obvious hemodynamic benefits seems to be surprising at first sight. However, the benefits of rhythm control could have been masked by adverse events and side effects caused by the AADs used in these studies. 26, 27 In other words: AAD related adverse effects may have neutralized the potential prognostic benefits of maintaining SR. 26 Indeed, amiodarone therapy, the AAD most often used in patients with HFrEF, has been associated with considerable discontinuation rates due to severe side effects and higher rates of noncardiovascular death. 24, 28, 29 Corroborating this hypothesis, regression analyses from the Atrial Although up to 50% of patients suffer an early recurrence after PVI within 3 months after the procedure, up to half of patients with early recurrence remain AF-free in a long-term follow-up. 33 Late recurrence more than 3 months after ablation occurs in 25%-40% of cases depending on the population of AF patients and the ratio of persistent to paroxysmal AF. 33 Overall, the efficacy of PVI is significantly higher than chronic treatment with AADs.
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| AF catheter ablation in heart failure
Currently, heart failure guidelines recommend considering AF ablation if a tachycardiomyopathy is suspected but the level of evidence is relatively low (recommendation class IIa, level of evidence C). 37 and hospitalization were also assessed as secondary endpoints. After a 24-month follow-up, 71 patients (70%) of ablation group were free from AF. In contrast to that, only 34% (P < 0.001) were free from AF recurrence in the conservative rhythm control group (amiodarone).
Importantly, an improvement of LVEF (P = 0.02), QoL (MLHFQ score, P = 0.04), and exercise performance by 6-minute walk distance (6MWD, P = 0.02) could also be detected in the ablation group compared to medical treatment. Furthermore, patients undergoing ablation had less hospitalizations compared to patients on amiodaroneregimen (31% vs 57%, P < 0.001, making up for a relative risk reduction of 45%). Although even the mortality rate formally was significantly lower in the ablation arm (8% vs 18%; P = 0.037), the event rate was low and the study had not been powered for mortality. 
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Of note, the Castle AF study emphasized the role of continuous rhythm monitoring for quantifying AF burden and predicting cardiac events. In line with this, a reduction of AF events, strokes, and hospitalization by remote monitoring in heart failure patients was demonstrated in the TELECART Study. function. 41 
| ADJUVANT AND FUTURE THERAPIES IN AF AND HF PATIENTS
In addition to catheter ablation of AF, adjuvant therapies may also be considered. Recent advances in the field of cardiac resynchronization therapy like multipolar pacing have shown promising results reducing cardiac mortality, hospitalization rate, and AF burden. 46, 47 In addition, catheter ablation results might be improved by novel therapies. Selectively targeting microRNAs might influence cardiac electrical and fibrotic remodeling after AF ablation. 48 As inflammation plays an important role in the process leading to AF recurrence after ablation, therapies modulating the inflammatory response such as corticosteroids or colchicine have been proposed. 49, 50 Recently, oral antioxidant treatment has shown to significantly lower inflammation markers but failed to proof a clinical effect in terms of AF recurrence. 
